Recent Updates
Recently added Catalysts
SRPT Negative Sentiment

Sarepta Therapeutics, Inc.: Company Investigated by the Portnoy Law Firm

Friday, April 14, 2023 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The Portnoy Law Firm has initiated an investigation into Sarepta Therapeutics, Inc. regarding potential securities fraud, prompting a call for affected investors to come forward. This news follows a significant drop in Sarepta's stock price after the FDA decided to hold an advisory committee meeting regarding the company's SRP-9001 therapy. The firm encourages investors who sustained losses to contact them for potential recovery options. Legal representation will be offered at no cost to the investors.
Price reaction · baseline $124.72 (2023-04-13 close) · hit after-hours · clean, no other SRPT news in the window
day 0 close · peak
-1.7%

Market Sentiment Analysis

CONCERNS & RISKS

  • Sarepta Therapeutics is under investigation for possible securities fraud.
  • The company experienced a stock price drop following a recent FDA advisory committee announcement.
  • The investigation may result in a class action lawsuit, adding to investor uncertainty.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+46%
120-day peak, hindsight
Typical move
16.8%
average across 4 past catalysts
Lead asset
Eteplirsen
Phase 3 · Muscular Dystrophy, Duchenne

Full Press Release Details

Investors can contact the law firm at no cost to learn more about recovering their losses
LOS ANGELES, April 14, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Sarepta Therapeutics, Inc. (“Sarepta Therapeutics” or the “Company”) (NASDAQ: SRPT) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Sarepta investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
On March 16, 2023, Sarepta Therapeutics announced that the U.S. FDA's Office of Therapeutics has decided to hold an advisory committee meeting for SRP-9001 in advance of the May 29, 2023 regulatory action date. This news caused a drop in the price of the company's stock.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
lesley@portnoylaw.com
Attorney Advertising

Frequently Asked Questions

How can Sarepta investors recover their losses?

Investors can contact the Portnoy Law Firm for a no-cost consultation to discuss recovery options.

What triggered the investigation into Sarepta Therapeutics?

An advisory committee meeting announcement by the FDA led to a drop in Sarepta's stock price.

Who should investors contact for legal support?

Investors should reach out to attorney Lesley Portnoy at 844-767-8529 or via email.

Is the case evaluation offered by the Portnoy Law Firm free?

Yes, the Portnoy Law Firm provides a complimentary case evaluation for investors.

What background does the Portnoy Law Firm have?

The firm has recovered over $5.5 billion for investors affected by corporate wrongdoing.

ShareAdd on Google
Tags: SRPT Viatris Investor Conferences Healthcare Sarepta Therapeutics securities fraud Portnoy Law Firm FDA
Last updated: Apr 14, 2023

Biotech snapshot

Cash runway
$788M liquidity · $0M/mo burn
Low dilution risk
Lead asset
EteplirsenPhase 3
Muscular Dystrophy, Duchenne →

Catalyst track record

+46%
best trade around SRPT's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for SRPT.

See every catalyst's timing & PoA →